Skip to main content

Advertisement

SpringerLink
Log in

Biochemical profiles and hormone receptors in prostate cancer

  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

Many attempts have been undertaken to develop a method to predict the responsiveness of prostate cancer to androgen ablation therapy. Even in the presence of highly sophisticated methods, however, the pretreatment level of serum testosterone presently seems to be the most significant parameter available to distinguish between poor and good responders. Neither tissue androgen levels nor androgen receptor content nor enzymatic indices bases on multiple biochemical variables are as indicative as the serum testosterone level. Much hope has been placed on determination of the subcellular distribution or the immunocytochemical localization of androgen receptors. All available data indicate that there must be other pathways that explain the differences between hormone-sensitive and hormone-insensitive cancer cells. Comprehension of these phenomena will fundamentally increase our knowledge and understanding of the biology of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adlercreutz H, Rannikko S, Kairento AL, Karonen SL (1981) Hormonal pattern in prostatic cancer: II. Correlation with primary response to endocrine treatment. Acta Endocrinol (Copenh) 98:634–640

    Google Scholar 

  2. Alanko A, Heinonen E, Scheinin T, Tolppanen E-M, Vihko R (1985) Significance of estrogen and progesterone receptors, diseasefree interval, and site of first metastasis on survival of breast cancer patients. Cancer 56:1696–1700

    Google Scholar 

  3. Anderson KM, Liao S (1968) Selective retention of dihydrotestosterone by prostatic nuclei. Nature 219:277–279

    Google Scholar 

  4. Aubel O van, Bolt-de Vries J, Blankenstein MA, Schröder FH (1988) Prediction of time to progression after orchiectomy by the nuclear androgen receptor content from multiple biopsy specimens in patients with advanced prostate cancer. Prostate 12:191–198

    Google Scholar 

  5. Barrack ER, Coffey DS (1980) The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem 255:7265–7275

    Google Scholar 

  6. Barrack ER, Coffey DS (1982) Biological properties of the nuclear matrix: steroid hormone binding. Recent Prog Hormone Res 38:133–195

    Google Scholar 

  7. Barrack ER, Tindal DJ (1987) A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. Prog Clin Biol Res 239:155–187

    Google Scholar 

  8. Barrack ER, Bujnovszky P, Walsh PC (1983) Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear saltresistant receptors. Cancer Res 43:1107–1116

    Google Scholar 

  9. Bartsch W, Horst HJ, Becker H, Nehse G (1977) Sex hormone binding globulin capacity, testosterone, 5α-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol (Copenh) 85:650–664

    Google Scholar 

  10. Bartsch W, Steins F, Becker H (1977) Hormone blood levels in patients with prostatic carcinoma and their relationship to the type of carcinoma growth differentiation. Eur Urol 3:47–52

    Google Scholar 

  11. Benson RC, Utz DC, Holicky E, Veneziale CM (1985) Androgen receptor binding activity in human prostate cancer. Cancer 55:382–388

    Google Scholar 

  12. Benson RC, Gorman PA, O'Brien PC, Holicky EL, Veneziale CM (1987) Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer 59:1599–1606

    Google Scholar 

  13. Blackard CE, Byar DP, Jordan WP Jr, Veterans Administration Cooperative Urological Research Group (1973) Orchiectomy for advanced prostatic carcinoma: a reevaluation. Urology 1:553–560

    Google Scholar 

  14. Blankenstein MA, Bolt-de Vries J, Foekens JA (1982) Nuclear androgen receptor assay in biopsy-size specimens of human prostatic tissue. Prostate 3:351–359

    Google Scholar 

  15. Brendler CB, Isaacs JT, Follansbee AL, Walsh PC (1984) The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. J Urol 131:694–700

    Google Scholar 

  16. Brendler CB, Isaacs JT, Walsh PC (1985) An update on the use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate. J Urol 133:368A

    Google Scholar 

  17. British Prostate Study Group (1979) Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostatic cancer. Br J Urol 51:382–389

    Google Scholar 

  18. Bruchovsky N, Wilson JD (1968) The conversion of testosterone to 5α-androstane-17β-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243:2012–2021

    Google Scholar 

  19. Bulbrook RD, Franks LM, Greenwood FC (1959) Hormone excretion in prostatic cancer: the early and late effects of endocrine treatment on urinary oestrogens, 17-keto-steroids and 17-ketogenic steroids. Acta Endocrinol (Copenh) 31:177–179

    Google Scholar 

  20. Byar DP, Sears ME, McGuire WL (1979) Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer 15:299–310

    Google Scholar 

  21. Chang C, Whelan CT, Popovich TC, Kokontis J, Liao S (1989) Fusion proteins containing androgen receptor sequences and their use in the production of poly- and monoclonal anti-androgen receptor antibodies. Endocrinology 125:1097–1099

    Google Scholar 

  22. Coffey DS, Isaacs JT (1981) Prostate tumor biology and cell kinetics — theory. Urology [Suppl] 17:40–53

    Google Scholar 

  23. Darbre PD, King RJB (1987) Progression to steroid insensitivity can occur irrespective of the presence of functional steroid receptors. Cell 51:521–528

    Google Scholar 

  24. DeSombre ER, Carbone PP, Jensen EV, McGuire WL, Wells SA Jr, Wittliff JL, Lipsett MB (1979) Steroid receptors in breast cancer. N Engl J Med 301:1011–1012

    Google Scholar 

  25. Devesa S, Silverman DT (1978) Cancer incidence and morbidity trends in the United States: 1935–1974. J Natl Cancer Inst 60:545–571

    Google Scholar 

  26. Fentie DD, Lakey WH, McBlain WA (1986) Applicability of nuclear androgen receptor quantification to human prostatic adenocarcinoma. J Urol 135:167–173

    Google Scholar 

  27. Garcia T, Lehrer S, Bloomer WD, Schachter B (1988) A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. Mol Endocrinol 2:785–791

    Google Scholar 

  28. Geller J, Albert JD (1985) DHT in prostate cancer tissue — a guide to management and therapy. Prostate 6:19–25

    Google Scholar 

  29. Geller J, Baron A, Kleinman S (1970) Pituitary lutenizing hormone reserve in elderly men with prostatic disease. J. Endocrinol 48:289–290

    Google Scholar 

  30. Ghanadian R, Auf G, Williams G, Davis A, Richards B (1981) Predicting the response of prostatic carcinoma to endocrine therapy. Lancet II:1418

    Google Scholar 

  31. Gonor SE, Lakey WH, McBlain WA (1984) Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma. J Urol 131:1196–1201

    Google Scholar 

  32. Gorelic LS, Lamm DL, Ramzy I, Radwin HM, Shain SA (1987) Androgen receptors in biopsy specimens of prostate adenocarcinoma. Cancer 60:211–219

    Google Scholar 

  33. Haapiainen R, Rannikko S, Alfthan O, Adlercreutz H, Finnish Prostate Group (1988) Pretreatment plasma levels of testosterone and sex hormone binding globulin binding capacity in relation to clinical staging and survival in prostatic cancer patients. Prostate 12:325–332

    Google Scholar 

  34. Hammond GL, Kontturi M, Maattala P, Puukka M, Vihko R (1977) Serum FSH, LH and prolactin in normal males and patients with prostatic disease. Clin Endocrinol 7:129–135

    Google Scholar 

  35. Harper ME, Peeling WB, Cowley T, Brownsey BG, Phillips ME, Groom G, Fahmy DR, Griffiths K (1976) Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma before and during oestrogen therapy. Acta Endocrinol (Copenh) 81:409–426

    Google Scholar 

  36. Harper ME, Pierrepoint CG, Griffiths K (1984) Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 20:477–482

    Google Scholar 

  37. Henry JA, Nicholson S, Farndon JR, Westley BR, May FEB (1988) Measurement of oestrogen receptor mRNA levels in human breast tumours. Br J Cancer 58:600–605

    Google Scholar 

  38. Hicks LL, Walsh PC (1979) A microassay for the measurement of androgen receptors in human prostatic tissue. Steroids 33:389–406

    Google Scholar 

  39. Huggins C, Hodges CV (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297

    Google Scholar 

  40. Isaacs JT, Isaacs WB, Coffey DS (1979) Models for development of nonreceptor methods for distinguishing androgen-sensitive and -insensitive prostatic tumors. Cancer Res 39:2652–2659

    Google Scholar 

  41. Ishikawa S, Soloway MS, Zwaag R van der, Todd B (1989) Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 141:1139–1142

    Google Scholar 

  42. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y (1987) Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355–4360

    Google Scholar 

  43. King RJB (1990) Receptors, growth factors and steroid insensitivity of tumours. J Endocrinol 124:179–181

    Google Scholar 

  44. Kumar V, Chambon P (1988) The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55:145–156

    Google Scholar 

  45. Kyprianou N, Williams H, Peeling WB, Davies P, Griffiths K (1986) Evaluation of biopsy techniques for androgen receptor assay in human prostatic tissue. Br J Urol 58:41–44

    Google Scholar 

  46. Lowe FC, Isaacs JT (1984) Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the Dunning R-3327 rat prostatic adenocarcinoma system as a model. Cancer Res 44:744–752

    Google Scholar 

  47. Lubahn DB, Joseph DP, Sar M, Tan J, Higgs HN, Larson RE, French FS, Wilson EM (1988) The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression. Mol Endocrinol 2:1265–1275

    Google Scholar 

  48. McNaught RW, Raymoure WJ, Smith RG (1986) Receptor interconversion model of hormone action: I. ATP-mediated conversion of estrogen receptors from a high to lower affinity state and its relationship to antiestrogen action. J Biol Chem 261:17011–17017

    Google Scholar 

  49. Migliaccio A, Di-Domenico M, Green S, de-Falco A, Kajtaniak EL, Blasi F, Chambon P, Auricchio F (1989) Phosphorylation on tyrosine of in vitro synthesized human estrogen receptor activates its hormone binding. Mol Endocrinol 3:1061–1069

    Google Scholar 

  50. Murphy LC, Dotzlaw H (1989) Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 3:687–693

    Google Scholar 

  51. Nelson WG, Pienta KJ, Barrack ER, Coffey DS (1986) The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem 15:457–475

    Google Scholar 

  52. Rannikko S, Kairento A-L, Karonen S-L, Adlercreutz H (1981) Hormonal pattern in prostatic cancer: I. Correlation with local extent of tumour, presence of metastases and grade of differentiation. Acta Endocrinol (Copenh) 98:625–633

    Google Scholar 

  53. Robinson MRG, Thomas BS (1971) Effect of hormonal therapy on plasma testosterone levels in prostatic cancer. Br Med J 4:391–394

    Google Scholar 

  54. Sadi MV, Walsh PC, Barrack ER (1990) Can immunocytochemical assay of androgen receptors (AR) predict androgen responsiveness of metastatic prostate cancer? J Urol 143:204A

    Google Scholar 

  55. Schulze H, Claus S (1990) Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry. Prostate 16:331–343

    Google Scholar 

  56. Shek LL, Godolphin W (1989) Survival with breast cancer: the importance of estrogen receptor quantity. Eur J Cancer Clin Oncol 25:243–250

    Google Scholar 

  57. Thorpe SM, Rose C (1986) Oestrogen and progesterone receptor determinations in breast cancer: technology and biology. Cancer Surv 5:505–525

    Google Scholar 

  58. Trachtenberg J, Walsh PC (1982) Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127:466–471

    Google Scholar 

  59. Voogt HJ de, Dingjan P (1978) Steroid receptors in human prostatic cancer. A preliminary evaluation. Urol Res 6:151–158

    Google Scholar 

  60. Wernert N, Gerdes J, Loy V, Seitz G, Scherr O, Dhom G (1988) Investigations of the estrogen (ER-ICA-test) and the progesterone receptor in the prostate and prostatic carcinoma on immunohistochemical basis. Virchows Arch [A] 412:387–391

    Google Scholar 

  61. Wolf RM, Schneider SL, Pontes JE, Englander L, Karr JP, Murphy GP, Sandberg AA (1985) Estrogen and progestin receptors in human prostatic carcinoma. Cancer 55:2477–2481

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Bochum, Marienhospital Herne, Widumer Strasse 8, W-4690, Herne 1, Germany

    H. Schulze

Authors
  1. H. Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schulze, H. Biochemical profiles and hormone receptors in prostate cancer. World J Urol 9, 64–68 (1991). https://doi.org/10.1007/BF00184035

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00184035

Keywords

Search

Navigation